HPV Vaccine: Triple Cancer Protection for Men and Women

The human papillomavirus (HPV) vaccine offers significant protection against multiple cancers for both men and women, with growing evidence supporting its role in preventing not only cervical cancer but also anal, oropharyngeal, penile, vulvar, and vaginal cancers.

According to the National Cancer Institute, HPV is a group of more than 200 related viruses, over 40 of which are spread through direct sexual contact. Among these, two types cause genital warts, and about a dozen can lead to certain cancers. The HPV vaccine, particularly Gardasil-9 which has been the only HPV vaccine used in the United States since 2016, protects against nine HPV types: 6, 11, 16, 18, 31, 33, 45, 52, and 58. Types 16 and 18 are responsible for about 70% of cervical cancers and a higher percentage of other HPV-related cancers, while the additional five types account for an extra 10% to 20% of cervical cancer cases.

The Centers for Disease Control and Prevention (CDC) recommends HPV vaccination for all individuals through age 26 who were not adequately vaccinated earlier. Routine vaccination is advised at ages 11 or 12, though it can begin as early as age 9. For those who receive their first dose before age 15, only two doses are needed, given 6 to 12 months apart. Individuals aged 15 to 26 who start the series later require three doses over six months. People with weakened immune systems aged 9 to 26 should also receive three doses.

CDC data indicates that HPV causes approximately 36,000 cancer cases annually in the United States among both men, and women. Vaccination before exposure to the virus provides the most effective protection, which is why early administration is emphasized. The vaccine has been shown to prevent infection with the HPV types most commonly linked to cancer and genital warts.

While the HPV vaccine is FDA-approved for individuals up to age 45, the CDC’s Advisory Committee on Immunization Practices does not recommend routine vaccination for all adults aged 27 to 45. Decisions in this age group should be made through shared clinical decision-making based on individual risk and prior vaccination history.

Recent studies highlighted in Arabic-language media have underscored the vaccine’s protective benefits for males, showing reduced risk of penile, anal, and oropharyngeal cancers. One major study noted that HPV vaccination may protect men from three specific cancer types, reinforcing the importance of gender-neutral vaccination efforts.

Health organizations continue to stress that HPV vaccination is a safe and effective public health measure with lasting protection. Extensive monitoring has confirmed its safety profile, and real-world data demonstrates significant declines in HPV infections and precancerous lesions since the vaccine’s introduction.